Company intelligence / Profile preview
Shanghai AB PharmaTech
Shanghai, Shanghai, Chinaabpharma.cn ↗
- Ownership
- Private
- Development stage
- Commercial
01
Overview
Shanghai AB PharmaTech develops multi-targeted tyrosine kinase inhibitors for oncology indications. Their lead assets are described in recent patent filings as novel small molecules with activity against a range of cancers. There are no publicly available clinical results or disclosed trial outcomes as of June 2025.
- Therapeutic areas
- Oncology
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Beyond the preview
Go deeper on Shanghai AB PharmaTech.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Shanghai AB PharmaTech.